Diagnostic Evaluation and Initial Treatment for Suspected Autoinflammatory Disorders in Adults
In adults presenting with recurrent unexplained fevers and systemic inflammation suggestive of autoinflammatory disease, immediately obtain genetic testing via next-generation sequencing (NGS) panel alongside measurement of inflammatory markers (CRP, ESR, ferritin), and initiate IL-1 inhibition (anakinra as first-line) if clinical suspicion is high while awaiting genetic confirmation, as early treatment prevents irreversible organ damage including AA amyloidosis. 1
Diagnostic Workup Algorithm
Initial Clinical Assessment - Key Features to Identify
Look specifically for these phenotypic patterns that distinguish autoinflammatory syndromes:
- Fever pattern: Recurrent/episodic versus persistent, duration of episodes, triggers
- Cutaneous manifestations: Urticarial rash (CAPS), migratory erythema, evanescent salmon-pink rash (Still's disease)
- Serosal inflammation: Chest pain (pleuritis/pericarditis), abdominal pain (peritonitis)
- Musculoskeletal: Inflammatory arthritis pattern, myalgias, bone pain
- Ocular involvement: Conjunctivitis, uveitis, papilledema
- Neurological symptoms: Aseptic meningitis, hearing loss
- Age of onset and family history: Childhood versus adult-onset, ethnic background (FMF more common in Mediterranean populations) 1, 2
Tier 1: Essential Laboratory and Imaging Studies
Laboratory markers during attacks:
- Acute phase reactants: CRP, ESR (both typically markedly elevated)
- Complete blood count with differential (leukocytosis with neutrophilia)
- Comprehensive metabolic panel (transaminitis common)
- Serum ferritin (markedly elevated >1000 ng/mL, often >5000 ng/mL suggests Still's disease or macrophage activation syndrome)
- Serum amyloid A (SAA) - tracks disease activity
- Urinalysis for proteinuria (AA amyloidosis screening) 1, 3
Exclude infectious/malignant mimics:
- Blood cultures, tuberculosis screening, HIV, hepatitis panel
- Age-appropriate malignancy screening
- Autoantibodies (ANA, RF, anti-CCP) - typically negative in autoinflammatory disease 3, 4
Tier 2: Genetic Testing - The Definitive Diagnostic Step
Genetic confirmation is required and should not be delayed 1:
- NGS panel is preferred covering NLRP3 (CAPS), TNFRSF1A (TRAPS), MVK (MKD), IL1RN (DIRA), and MEFV (FMF) 1, 2
- Sanger sequencing acceptable if strong clinical suspicion for specific syndrome or to validate NGS findings
- Deep sequencing may be necessary for CAPS and TRAPS to detect somatic mosaicism not identified by standard methods 1
- Whole exome/genome sequencing (WES/WGS) for DIRA when standard testing negative, as large deletions may be missed 1
Critical caveat: Low-penetrance variants (NLRP3, TNFRSF1A R121Q) may present atypically with different treatment responses - refer these patients to specialty centers 1
Tier 3: Advanced Imaging When Diagnosis Unclear
- 18F-FDG PET/CT: Identifies occult inflammation, malignancy, or vasculitis when diagnosis remains elusive after initial workup 3
- Echocardiography if pericarditis suspected
- Joint imaging (ultrasound/MRI) to characterize arthritis pattern
Initial Treatment Strategy
Immediate Management Based on Clinical Phenotype
For IL-1 mediated diseases (CAPS, TRAPS, MKD, DIRA):
Anakinra (IL-1 receptor antagonist) is first-line therapy 1, 5:
- Dosing: 100 mg subcutaneously daily (adults); may require up to 2-8 mg/kg/day in severe cases
- Rapid response expected within 24-48 hours
- Safe to initiate empirically while awaiting genetic confirmation if clinical suspicion high
- Alternative IL-1 inhibitors: Canakinumab (150 mg SC every 4-8 weeks) or rilonacept if anakinra inadequate 1, 5
For FMF:
Colchicine is first-line 2:
- Start 0.5-1.0 mg daily, titrate to 1.5-2.0 mg daily based on response
- Emphasize adherence - non-adherence is major cause of apparent "resistance"
- If colchicine-resistant (defined by persistent attacks despite adequate dosing and adherence): escalate to IL-1 inhibitors (anakinra or canakinumab) 2
For Adult-Onset Still's Disease (AOSD):
Treatment escalation based on severity 6, 7, 8:
- Mild-moderate: High-dose corticosteroids (prednisone 0.5-1 mg/kg/day)
- Severe or corticosteroid-dependent: IL-1 inhibition (anakinra) or IL-6 inhibition (tocilizumab)
- Anakinra often preferred for rapid control; tocilizumab for sustained remission 7, 8
Treat-to-Target Approach
The goal is complete control of inflammation, not just symptom improvement 1:
- Clinical remission: No fever, no rash, no active arthritis, no serosal inflammation
- Biochemical remission: Normalization of CRP, ESR, SAA
- Monitor every 3-6 months: Clinical assessment, inflammatory markers, urinalysis (AA amyloidosis surveillance), audiology (for CAPS/MKD), ophthalmology (for uveitis risk)
- Adjust therapy if targets not met - inadequate control leads to AA amyloidosis, the most devastating complication 1
Critical Pitfalls to Avoid
Delaying genetic testing: Order NGS panel immediately; genetic diagnosis informs prognosis, enables genetic counseling, and validates treatment decisions 1
Waiting for genetic results to treat: If clinical phenotype strongly suggests IL-1 mediated disease and patient has active inflammation, start anakinra empirically - delayed treatment risks irreversible organ damage 1, 5
Accepting partial response: Persistent elevation of inflammatory markers despite clinical improvement predicts AA amyloidosis development. Escalate therapy to achieve complete biochemical control 1
Misinterpreting low-penetrance variants: R121Q in TNFRSF1A and certain NLRP3 variants may not cause classic disease - refer to specialty centers rather than assuming diagnosis confirmed 1
Missing adult-onset presentations: Autoinflammatory diseases increasingly recognized in adults, including de novo adult-onset cases. Don't exclude diagnosis based on age alone 4, 9, 10
Overlooking AA amyloidosis screening: Check urinalysis for proteinuria at every visit. If proteinuria develops, confirm with tissue biopsy and intensify anti-inflammatory therapy immediately 1
When to Refer to Specialty Centers
Refer patients with:
- Clinical phenotype suggestive of autoinflammatory disease but negative genetic testing
- Low-penetrance or novel variants of uncertain significance
- Inadequate response to standard IL-1 or IL-6 inhibition
- Development of AA amyloidosis requiring nephrologist co-management
- Need for family genetic counseling 1